Supreme Court Decision Hangs In Balance After Hikma-Amarin Skinny-Label Oral Arguments

Hatch-Waxman & Biologics Chair Chad Landmon discusses how the U.S. Supreme Court’s consideration of the Hikma v. Amarin case highlights ongoing uncertainty around “skinny label” generics and induced patent infringement. He notes that the justices appear inclined to avoid creating a sweeping new legal standard, instead favoring a narrower, fact-specific approach grounded in existing inducement principles. Landmon emphasizes that the Court’s eventual decision could still have significant implications for generic drug makers, particularly in balancing patent protection with access to lower-cost medicines.